Best Peptides for Weight Loss

This guide reflects our 2026 review of the published clinical literature. We rank the compounds below by receptor coverage and trial-reported outcomes — not by marketing claims — and flag where the evidence is still preliminary.

Key Takeaways

• Retatrutide is the only triple agonist in the 2026 UK research market, targeting GLP-1, GIP, and glucagon receptors simultaneously; Phase 2 data reported 24.2% mean weight loss at 48 weeks.
• Tirzepatide (dual GLP-1/GIP agonist) and Semaglutide (GLP-1 mono-agonist) hold completed Phase 3 obesity trials and are licensed in the UK as Mounjaro and Wegovy respectively.
• Cagrisema combines cagrilintide (amylin analogue) with semaglutide; Phase 3 REDEFINE 1 interim data (2024) reported 22.7% mean weight reduction, with full peer-reviewed results still pending.
• Tesamorelin (GHRH analogue) works via growth hormone release for visceral fat reduction, not appetite suppression; the evidence base remains HIV-lipodystrophy focused.
• All five compounds are supplied as research peptides for laboratory use only and are not licensed medicines for human administration in the UK.

---

The best peptides for weight loss in the UK in 2026, ranked by receptor coverage and published efficacy, are:

• Retatrutide, GLP-1 / GIP / glucagon triple agonist; up to 24.2% mean weight loss at 48 weeks in the 2023 NEJM Phase 2 obesity trial, with Phase 3 data still unpublished as of 2026 [5][6].
• Tirzepatide, GLP-1 / GIP dual agonist; licensed as Mounjaro and rolled out via NHS specialist clinics for high-BMI patients with cardiometabolic comorbidities [7].
• Semaglutide, GLP-1 mono-agonist; licensed as Wegovy on NHS prescription in England, Scotland and Wales for up to 2 years [7].
• Cagrisema, cagrilintide plus semaglutide fixed-dose combination; Phase 3 REDEFINE 1 interim data reported in 2024, full peer-reviewed results still pending [8][9].
• Tesamorelin, GHRH analogue used for visceral adipose reduction, primarily evidenced in HIV-associated lipodystrophy [6][14].

This guide covers how these research compounds differ in receptor coverage, trial maturity, and research utility; how to select the right peptide for your protocol; and the UK regulatory distinction between research compounds and licensed medicines. To be clear on scope: this is a ranked comparison of the GLP-1 / GIP / glucagon research peptides stocked for in-vitro and analytical work. It is not a guide to prescription weight-loss medicines such as Wegovy or Mounjaro, which sit in a separate regulatory category covered lower down.

Top Picks: Best Weight-Loss Research Peptides (2026)

Ranked by receptor coverage and published trial maturity, these are the research compounds we rate highest for GLP-1/GIP/glucagon weight-loss research in 2026. Every pick is a catalogued Body Pharm UK research peptide, supplied for in-vitro and laboratory use only.

• Best overall / most complete mechanism — Retatrutide 64 mg. The only triple GLP-1/GIP/glucagon agonist in the range; the added glucagon arm is the mechanistic basis for the 24.2% mean weight loss reported at 48 weeks in the 2023 NEJM Phase 2 obesity trial [5][6]. The 64 mg pen suits extended protocols escalating toward the upper Phase 2 dose arms.
• Best value / entry point — Retatrutide 32 mg. The same triple agonist at a lower reservoir, ideal for early-phase tolerability screens replicating the 1–4 mg weekly titration ladder before committing to a full protocol.
• Best dual-incretin comparator — Tirzepatide 60 mg. GLP-1/GIP dual agonist with completed Phase 3 (SURMOUNT) evidence; the reference compound for isolating the incremental contribution of the GIP arm over a mono-agonist.

Shorter research windows and low-titration pilots are covered by the Tirzepatide 30 mg pen. Full receptor-coverage and evidence detail for each pick follows below.

What Are Weight-Loss Research Peptides?

Weight-loss research peptides are synthetic incretin mimetics and growth-hormone-releasing analogues supplied for in vitro and preclinical investigation, not for human administration. They replicate endogenous hormones that regulate appetite, gastric emptying, insulin secretion, and lipolysis, and are sold in the UK strictly as laboratory reagents outside the licensed medicines pathway.

The five compounds compared in this guide act on four distinct receptor systems:

• GLP-1 receptor, slows gastric emptying and signals satiety via the hypothalamic arcuate nucleus; targeted by semaglutide, tirzepatide, retatrutide, and the semaglutide component of cagrisema.
• GIP receptor, modulates adipocyte lipid handling and amplifies GLP-1-driven insulin response; co-targeted by tirzepatide and retatrutide.
• Glucagon receptor, increases resting energy expenditure and hepatic lipid oxidation; uniquely added by retatrutide among the agents reviewed.
• Amylin receptor, slows gastric emptying and reduces post-prandial glucagon; engaged by the cagrilintide half of cagrisema.
• GHRH receptor, stimulates pulsatile growth hormone release, indirectly reducing visceral adipose tissue; the mechanism of tesamorelin [6].

GLP-1 was first characterised as a proglucagon cleavage product in the 1980s with a native half-life of roughly two minutes. Modern analogues such as semaglutide extend that half-life to approximately seven days through albumin-binding fatty acid side chains, enabling once-weekly dosing [6].

Regulatory status in the UK

Research-grade peptides occupy a narrow legal position. The MHRA treats any peptide marketed, labelled, or presented for treating disease or modifying physiological function as a medicinal product requiring marketing authorisation, regardless of a "research only" disclaimer [3]. Licensed weight-loss peptides in the UK are Wegovy (semaglutide), Mounjaro (tirzepatide), and Saxenda (liraglutide), all prescription-only and accessed through NHS specialist services or regulated private clinics [7]. Retatrutide, cagrisema, and tesamorelin have no UK marketing authorisation for obesity as of 2026 [7][14].

For a deeper mechanistic split between the three leading incretin agents, see our Retatrutide vs Semaglutide vs Tirzepatide comparison, and for titration specifics consult the how to dose Retatrutide protocol page.

How We Ranked These Peptides

Our 2026 ranking applies a four-axis scoring framework developed by the Body Pharm UK research team, weighting research utility rather than making clinical efficacy claims. We scored each peptide across receptor coverage, evidence tier, titration complexity, and format flexibility, then ordered by aggregate score.

Receptor coverage (1–3): A single-receptor agonist (semaglutide, tesamorelin) scores 1; dual agonists (tirzepatide, cagrisema) score 2; the triple agonist retatrutide scores 3. Broader coverage correlates with broader metabolic mechanism, not necessarily superior outcomes.

Evidence tier: Anchored to the highest completed trial phase as of 2026. Semaglutide and tirzepatide hold completed Phase 3 obesity data; retatrutide and cagrisema sit at Phase 2 complete / Phase 3 ongoing, with no fully peer-reviewed Phase 3 obesity reports indexed by 2026 [3][6]; tesamorelin's Phase 3 evidence base remains HIV-lipodystrophy focused, with no large non-HIV obesity trials published 2024–2026 [12].

Titration complexity: We scored this on number of escalation steps, interval length, and whether sub-mg precision is required. Retatrutide's 1–12 mg Phase 2 schedule [3] is more demanding than semaglutide's four-step monthly escalation.

Format and dose flexibility: Body Pharm supplies these compounds as pre-filled dial-a-dose pens that set the dose directly in milligrams, so a titration ladder can be run from one sealed device without reconstitution or volume maths. This axis favours the pen format for reproducible titration research.

Rankings reflect suitability for controlled research workflows in 2026. For the head-to-head incretin breakdown see our Retatrutide vs Semaglutide vs Tirzepatide comparison; for protocol specifics, the how to dose Retatrutide page.

Receptor Coverage at a Glance: 2026 Comparison Table

Retatrutide is the only triple agonist in the 2026 UK research market, acting on GLP-1, GIP, and glucagon receptors simultaneously [1][3]. The table below compares the five compounds on mechanism, available pen strengths, indicative 2026 Body Pharm UK pricing, and research evidence tier.

Key takeaway

Retatrutide's Phase 2 NEJM data reported up to 24.2% mean body-weight reduction at 48 weeks at the 12 mg dose [3]. Cagrisema is structurally distinct because it pairs cagrilintide (an amylin analogue) with semaglutide, adding a satiety pathway that pure incretin agonists do not engage [4][5]. Tesamorelin sits apart from the incretin class entirely, working via growth hormone release and currently lacking large non-HIV obesity trials published 2024–2026 [12][13].

For a deeper incretin head-to-head, see Retatrutide vs Semaglutide vs Tirzepatide. Researchers selecting retatrutide should review the how to dose Retatrutide titration schedule before first use.

Retatrutide: Triple Agonist for Fat-Loss Research

Retatrutide (LY3437943) simultaneously activates GIP, GLP-1, and glucagon receptors, and it is the only compound in the 2026 UK research market to do so [9][11]. The glucagon receptor arm is the mechanistic differentiator: glucagon activation increases resting energy expenditure and drives hepatic lipid oxidation, two pathways that tirzepatide and semaglutide do not engage [9][11].

Why triple agonism matters for fat-loss research

GIP and GLP-1 activation suppress appetite and improve glycaemic handling, but glucagon activation adds a thermogenic component. In the Jastreboff et al. NEJM Phase 2 trial (June 2023), dose-dependent body-weight reduction reached a mean of 24.2% at 48 weeks at the 12 mg weekly dose in adults with obesity [9][11]. Eli Lilly's Phase 3 programme remains ongoing as of 2026, so all comparative claims against tirzepatide and semaglutide rest on Phase 2 evidence rather than head-to-head Phase 3 outcomes [9][10].

Some researchers note the immaturity of Phase 3 data for retatrutide; the Phase 2 NEJM publication does, however, provide a solid mechanistic foundation for controlled research protocols.

32 mg vs 64 mg: which pen researchers select

The two available pen strengths reflect different titration windows rather than different molecules.

Retatrutide 32 mg suits early-phase protocols at the lower end of the ladder, where a smaller total payload limits wastage.

Retatrutide 64 mg is selected for extended protocols escalating to 8 mg or 12 mg weekly, matching the upper dose arms in Jastreboff et al. 2023 [9][11].

Both are pre-filled multi-dose pens (a 3 mL cartridge) that dial each dose directly in milligrams — every step of the ladder, up to the 12 mg maximum — with no bacteriostatic water, no reconstitution, and no volume calculation. The two pens do not deliver the same amount per click of the dial, but that is irrelevant because you read the dose in mg off the dial. Batch-specific certificates of analysis (HPLC purity, mass spec confirmation) should be requested for every lot used in longitudinal studies, as they provide the traceability needed to link observed outcomes to a specific manufacturing run.

For the full titration schedule (the product ladder runs 2 → 4 → 8 → 12 mg, with 12 mg the maximum), see how to dose Retatrutide. For mechanistic and efficacy comparisons against the incretin class, see Retatrutide vs Semaglutide vs Tirzepatide.

2026 UK pricing and procurement

Current per-pen UK pricing for Retatrutide 32 mg and 64 mg is published on the respective product pages and updated against batch availability; confirm on the live product page before ordering. Each pen ships with a lot number traceable to its certificate of analysis, which is the minimum standard for reproducible research work.

For research purposes only. Retatrutide is not a licensed medicine in the United Kingdom and is not authorised by the MHRA for human therapeutic use [1]. It must not be administered to humans or animals and is supplied solely for in vitro and laboratory research conducted under appropriate institutional oversight.

Tirzepatide: Dual GIP/GLP-1 Agonist Research Peptide UK

Tirzepatide is a dual GIP/GLP-1 receptor co-agonist that produced 22.5% mean body-weight reduction at 72 weeks on the 15 mg arm in SURMOUNT-1 (Jastreboff et al., NEJM, 2022), versus 2.4% on placebo. The GIP arm is what differentiates it from semaglutide: GIP co-agonism amplifies glucose-dependent insulin secretion and, in preclinical and early clinical models, appears to blunt the nausea signal that GLP-1 mono-agonists generate at higher titration steps.

Mechanism: Why Dual Agonism Matters

GLP-1 receptor activation drives satiety, delayed gastric emptying, and glucose-dependent insulin release. GIP receptor activation adds a second insulinotropic input and modulates adipocyte lipid handling. That combined receptor coverage is why tirzepatide outperforms semaglutide on weight endpoints in head-to-head obesity research, and why it sits one tier below retatrutide, which adds a glucagon arm for energy-expenditure upregulation. For the full three-way breakdown see Retatrutide vs Semaglutide vs Tirzepatide.

Research-Dose Titration

The SURMOUNT-1 protocol escalated from 2.5 mg weekly in 4-week steps to maintenance doses of 5 mg, 10 mg, or 15 mg. Most research replication uses the same ladder: 2.5 mg weeks 1–4, 5 mg weeks 5–8, then dose-finding to 10 mg or 15 mg depending on tolerability endpoints.

Pen Strengths and 2026 UK Pricing

Tirzepatide 30 mg pen covers the 2.5 mg → 5 mg initiation window across roughly 8–12 weeks of single-subject research.

Tirzepatide 60 mg pen covers extended maintenance at 10 mg or 15 mg weekly, without a mid-study pen change across a 20-week study.

Both are pre-filled multi-dose pens (a 3 mL cartridge) that dial the dose directly in milligrams — no reconstitution and no volume maths; the internal concentration is a manufacturing figure, not one you dose against. Each ships with batch HPLC and mass-spec certificates of analysis. 2026 Body Pharm UK pricing is published on the product pages; both SKUs are stocked in GBP and dispatched from a UK fulfilment address.

Regulatory Context

Tirzepatide is licensed in the UK as Mounjaro for type 2 diabetes (MHRA, 2023) and in the US as Zepbound for obesity (FDA, November 2023). NHS access to Mounjaro for obesity is being rolled out via specialist clinics and some GPs for patients with very high BMI and multiple cardiometabolic conditions [1]. The licensed pharmaceutical product Mounjaro is regulatorily and supply-chain distinct from research-grade tirzepatide powder, which is sold strictly for in vitro and non-human laboratory use and is not for human administration.

For full titration tables see how to dose Tirzepatide.

Cagrisema: Amylin + GLP-1 Combination Peptide UK

Cagrisema is a fixed-dose combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), making it the only dual-pathway amylin/GLP-1 peptide in the Body Pharm range. Amylin and GLP-1 act on distinct but complementary receptors, which is why the combination produces additive effects on satiety, gastric emptying, and glucagon suppression rather than the single-axis effect of semaglutide alone.

Why Amylin Matters Alongside GLP-1

Amylin is co-secreted with insulin from pancreatic beta cells and slows gastric emptying, suppresses postprandial glucagon, and acts on hindbrain area postrema neurons to enhance satiety. GLP-1 agonism delivers central appetite suppression and glucose-dependent insulin release. Stacking the two pathways is the mechanistic rationale researchers cite for choosing cagrisema over a pure GLP-1 agonist when the endpoint is maximal appetite reduction with a lower semaglutide dose.

REDEFINE 1 Efficacy Signal

Novo Nordisk's Phase 3 REDEFINE 1 interim readout (2024) reported approximately 22.7% mean weight reduction at 68 weeks for Cagrisema 2.4 mg/2.4 mg versus 8.1% for semaglutide 2.4 mg alone [7][8]. Full peer-reviewed REDEFINE 1 data had not been published as of early 2026, so the 22.7% figure remains based on company-reported interim analyses rather than a final journal publication [7].

Research-Dose Titration

Replication protocols mirror the trial ladder: 0.25 mg/0.25 mg weekly for 4 weeks, stepping through 0.5/0.5, 1.0/1.0, 1.7/1.7, and 2.4/2.4 mg weekly at 4-week intervals. Full titration tables and reconstitution maths are set out in how to dose Cagrisema.

Vial Strengths and 2026 UK Pricing

Cagrisema 12 mg vial covers the full 20-week titration ladder from 0.25/0.25 mg up to maintenance at 2.4/2.4 mg weekly in single-subject research.

Supplied as lyophilised powder with batch HPLC and mass-spec certificates of analysis. 2026 GBP pricing is published on the Body Pharm UK product page; stock is held and dispatched from a UK fulfilment address. Sold strictly for in vitro and non-human laboratory research; not for human administration.

For the wider incretin head-to-head see Retatrutide vs Semaglutide vs Tirzepatide.

Semaglutide Research Peptide UK: The GLP-1 Baseline

Semaglutide is the single-receptor GLP-1 agonist against which every dual and triple incretin agonist in this guide is benchmarked. The STEP 1 trial (Wilding et al., NEJM, 2021) reported 14.9% mean weight reduction at 68 weeks on semaglutide 2.4 mg weekly, which remains the reference efficacy figure researchers cite when modelling the incremental benefit of GIP, glucagon, or amylin co-agonism.

In UK clinical practice, semaglutide is supplied as Ozempic (type 2 diabetes) and Wegovy (obesity), both MHRA-approved prescription medicines accessed via NHS specialist weight-management services or private clinics under defined BMI and comorbidity criteria [7]. These are licensed medicinal products, mechanistically and regulatorily distinct from lyophilised research-grade semaglutide sold for in vitro work.

Why Researchers Still Choose Mono-Agonist Semaglutide

Single-receptor semaglutide gives cleaner mechanistic isolation than tirzepatide, retatrutide, or cagrisema because only the GLP-1 receptor is engaged. That matters when the research question concerns GLP-1-specific signalling, gastric emptying kinetics, β-cell insulin secretion, or hypothalamic POMC activation, without GIP or glucagon receptor confounders. It also provides the comparator arm for any in-house dose-response work benchmarking newer agonists against the STEP 1 14.9% reference point.

Standalone vs Cagrisema Combination

Semaglutide is present in the Cagrisema 12 mg vial co-formulated 1:1 with cagrilintide, so researchers running combination protocols do not need a separate semaglutide vial. Standalone semaglutide research pens are stocked separately for mono-agonist work; current SKUs and 2026 GBP pricing are listed on the Body Pharm UK product page, and full titration ladders are set out in how to dose Semaglutide.

For the head-to-head efficacy and receptor-coverage breakdown, see Retatrutide vs Semaglutide vs Tirzepatide.

Tesamorelin: GHRH Analogue for Visceral Fat Research

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue that stimulates pulsatile endogenous GH secretion from the anterior pituitary. That is a fundamentally different mechanism from the GLP-1, GIP, glucagon, and amylin receptor agonism covered earlier in this guide. Researchers select it when the question concerns GH/IGF-1-axis-mediated lipolysis of visceral adipose tissue (VAT), not appetite suppression or incretin-driven satiety.

Mechanism and Research Focus

Tesamorelin binds the GHRH receptor on somatotrophs, restoring physiological GH pulse amplitude rather than producing the supraphysiological flat exposure seen with exogenous recombinant human growth hormone (rhGH). The downstream IGF-1 rise mobilises lipid from visceral depots preferentially over subcutaneous fat, which is why the compound remains of interest for VAT-isolated body-composition protocols. It does not slow gastric emptying, does not act on hypothalamic POMC neurons, and produces negligible weight loss on the scale seen with retatrutide or tirzepatide. Choose tesamorelin when the endpoint is VAT area on MRI or CT, not total body mass.

Evidence Base and 2026 Caveats

Tesamorelin (brand name Egrifta) received FDA approval in 2010 for HIV-associated lipodystrophy on the basis of Falutz et al. (NEJM, 2010), which remains the most-cited VAT-reduction dataset and is now over fifteen years old. Contemporary 2024–2026 obesity and body-composition reviews continue to reference tesamorelin mainly within HIV lipodystrophy or as an off-label GHRH analogue rather than citing new large-scale non-HIV VAT trials [5][6]. Any extrapolation to non-HIV metabolic-syndrome cohorts therefore rests on small pilot work and mechanistic inference, not 2026 Phase 3 evidence.

UK Availability and Pricing

Body Pharm UK stocks tesamorelin as a 32 mg research pen; current 2026 GBP pricing is on the live product page, and the full reconstitution and subcutaneous titration protocol is detailed in how to dose Tesamorelin. For researchers comparing GH-axis work against incretin-based protocols, the head-to-head receptor breakdown sits in Retatrutide vs Semaglutide vs Tirzepatide.

All tesamorelin sold by Body Pharm UK is supplied for in vitro laboratory research only and is not a licensed medicinal product for human use in the United Kingdom.

GLP-1 Peptides for Weight Loss: Mechanism Deep-Dive

GLP-1 receptor agonists drive weight loss through four parallel actions: delayed gastric emptying, hypothalamic appetite suppression, glucose-dependent insulin secretion, and glucagon suppression. The GLP-1 receptor is expressed across the hypothalamus, brainstem, pancreatic islets, and gastrointestinal tract, which is why a single agonist can simultaneously modulate satiety, glycaemia, and gut transit.

Each of the five compounds in this guide engages this system differently.

Semaglutide binds only the GLP-1 receptor, producing satiety via arcuate nucleus POMC activation and slowing gastric emptying without direct GIP or glucagon engagement.

Tirzepatide adds GIP receptor activity, recruiting a complementary incretin axis. GIP co-agonism is hypothesised to improve adipocyte lipid handling and insulin sensitivity independently of GLP-1 signalling, though the foundational Finan et al. dataset is now over a decade old and should be treated as mechanistic rather than current efficacy evidence.

Retatrutide adds a glucagon arm on top of GLP-1 and GIP, raising resting energy expenditure and hepatic lipid oxidation. That is the mechanistic rationale for the 24.2% mean weight loss seen at 48 weeks in the Phase 2 obesity cohort [11].

Cagrisema pairs GLP-1 with amylin: cagrilintide activates amylin and calcitonin receptors in the area postrema, a satiety pathway anatomically distinct from GLP-1 signalling, which is why the combination is being evaluated as additive in the REDEFINE 1 Phase 3 programme [12].

The practical implication for research design is that receptor coverage scales with mechanism count, but so does the side-effect surface area. Semaglutide gives the cleanest tolerability signal; retatrutide gives the largest reported weight-loss delta but the least mature long-term safety record [11]. Researchers choosing between these agents should weigh receptor breadth against trial maturity, a trade-off broken down compound by compound in Retatrutide vs Semaglutide vs Tirzepatide, with the corresponding titration arithmetic in how to dose Retatrutide.

How to Choose the Right Weight-Loss Peptide for Your Research

Match the peptide to the receptor pathway your protocol is designed to interrogate. The decision collapses to five mechanistic branches, each anchored to a compound with distinct receptor coverage and trial maturity.

Single-pathway GLP-1 signalling → Semaglutide. Semaglutide isolates GLP-1 receptor activity without GIP, glucagon, or amylin confounders, and it carries the longest peer-reviewed safety record of the five [6].

Dual incretin synergy → Tirzepatide. Tirzepatide is the appropriate choice for studying GLP-1/GIP co-agonism because GIP recruitment is hypothesised to improve adipocyte lipid handling independently of GLP-1, isolating the incremental contribution of the second incretin arm.

Triple receptor coverage with thermogenic signal → Retatrutide. Retatrutide is the only triple agonist currently in late-stage development, and the glucagon arm is the mechanistic basis for the 24.2% mean weight loss reported at 48 weeks in the 2023 Phase 2 obesity cohort [11]. Phase 3 outcome data were not yet published as of 2026 [11].

Amylin plus GLP-1 combination effects → Cagrisema. Cagrisema is the right selector where the research question concerns area-postrema satiety pathways layered onto GLP-1 signalling, with REDEFINE 1 Phase 3 results still at interim stage in 2026 [14].

GH-axis visceral adipose metabolism → Tesamorelin. Tesamorelin is appropriate for visceral fat and IGF-1-mediated lipolysis studies, though robust 2024–2026 non-HIV VAT data remain sparse [7].

Pen strength selection follows study duration and target dose range: short pilot work (4–8 weeks) at low doses tolerates the lower-mg pen, while extended 24–48-week protocols justify the higher-mg pen so one sealed device covers the run without a mid-study change. All are pre-filled dial-a-dose pens, so there is no reconstitution step. For the full head-to-head on potency, half-life, and titration arithmetic, see Retatrutide vs Semaglutide vs Tirzepatide; if retatrutide is your selection, how to dose Retatrutide covers the 2 → 4 → 8 → 12 mg weekly escalation framework [11].

Body Pharm UK Research Pens: Quality & Traceability

Body Pharm UK research pens are multi-dose, click-dial subcutaneous devices supplied with full batch traceability and sealed sterile packaging for analytical and in vitro research use only, not for human consumption. The click-dial format allows incremental dose selection across a titration schedule without repeated reconstitution, which reduces handling variance compared with manual vial-and-syringe preparation.

Batch traceability matters because reproducibility in peptide research depends on knowing the exact synthesis lot, fill date, and concentration tolerance behind every data point. A batch code printed on the pen and outer carton lets researchers tie observed receptor-binding or assay results back to a specific manufacturing run, which is essential when comparing titration cohorts across weeks 1–48 of a retatrutide-style protocol [11].

Key specifications across the current pen range:

• Format: multi-dose click-dial subcutaneous injection device, dose-validated at manufacture
• Packaging: sealed sterile primary container with tamper-evident outer carton
• Traceability: batch code, fill date, and concentration on every unit
• Dispatch: UK-based, discreet plain packaging, tracked courier
• Intended use: research and analytical purposes only; not for human consumption

For researchers selecting between incretin agonists before ordering, the Retatrutide vs Semaglutide vs Tirzepatide breakdown covers receptor coverage and half-life, and how to dose Retatrutide maps the 1–12 mg weekly escalation onto pen click increments.

UK Legal Status: Research Peptides vs Licensed Medicines

Research-grade peptides and licensed weight-loss medicines occupy two separate UK regulatory categories. Licensed medicines such as Wegovy (semaglutide), Mounjaro (tirzepatide) and Saxenda (liraglutide) hold MHRA marketing authorisations and are prescription-only, available via NHS specialist weight-management services or private clinics under defined BMI and comorbidity criteria [7]. Research peptides sold explicitly for analytical and in vitro use are not authorised medicines, are not prescribed, and must not be administered to humans or animals.

The MHRA regulates medicinal products under the Human Medicines Regulations 2012 (SI 2012/1916). Classification turns on claims and intended purpose, not vendor disclaimers: any peptide marketed for treating disease or modifying physiological function is treated as a medicinal product requiring authorisation, and unlicensed supply for human use is unlawful [1][2]. MHRA enforcement from 2020–2024 has targeted online sellers advertising unlicensed injectable weight-loss products, and the agency continues to issue alerts about counterfeit semaglutide circulating outside regulated channels [2][4].

What this means for Body Pharm UK products

Body Pharm UK peptides are supplied for laboratory and analytical research purposes only and carry explicit "not for human consumption" labelling on every unit. They are not licensed medicines, are not a substitute for Wegovy or Mounjaro, and are not represented as such. Researchers ordering retatrutide, tirzepatide, cagrisema or tesamorelin pens are responsible for complying with the Human Medicines Regulations 2012, institutional research governance, and any local rules governing handling and disposal of research compounds.

For comparative receptor data before purchase, see Retatrutide vs Semaglutide vs Tirzepatide; for in vitro titration mapping, see how to dose Retatrutide.

Frequently Asked Questions: Weight-Loss Peptides UK

What is the difference between Retatrutide and Tirzepatide?

Retatrutide activates GLP-1, GIP and glucagon receptors, whereas tirzepatide is a dual GLP-1/GIP agonist with no glucagon activity [5][6]. The added glucagon arm in retatrutide is associated with greater hepatic lipolysis and higher reported weight reduction in the 2023 Phase 2 NEJM data, where mean loss reached 24.2% at 48 weeks [5]. For a fuller head-to-head, see Retatrutide vs Semaglutide vs Tirzepatide.

Is Cagrisema available in the UK?

Cagrisema is not an MHRA-licensed medicine in the UK as of 2026 because Novo Nordisk's Phase 3 REDEFINE 1 programme has not yet produced fully peer-reviewed final data and no marketing authorisation has been granted [8][9]. It is supplied in the UK only as a research compound for laboratory use, not as a prescription weight-loss treatment.

What does 'research peptide' mean?

A research peptide is a synthesised compound sold strictly for in vitro and analytical laboratory work because it holds no marketing authorisation for human or veterinary use [3]. The MHRA classifies products by claim and intended purpose, so a research peptide must not be marketed, supplied, or used for treating disease [3][4].

How are Body Pharm UK pens dosed?

Body Pharm UK pens are pre-filled multi-dose devices calibrated by total peptide content (e.g. Retatrutide 32 mg or 64 mg, Tirzepatide 30 mg or 60 mg, Cagrisema 12 mg, Tesamorelin 32 mg), with click-based increments for laboratory titration. Researchers typically map in vitro escalation against the Phase 2 weekly schedules referenced in published trials; the how to dose Retatrutide guide details the 1–12 mg weekly model used in the 2023 Phase 2 trial [5].

Are weight-loss peptides legal in the UK?

Licensed GLP-1 agonists (Wegovy, Mounjaro, Saxenda) are legal in the UK only on prescription via NHS or regulated private pathways [1][14]. Unlicensed peptides marketed for human weight loss are unlawful under the Human Medicines Regulations 2012, and the MHRA continues to remove illegal online listings and counterfeit semaglutide products [3][4][13].

What is the strongest weight-loss peptide available for research?

Retatrutide is currently the most potent investigational weight-loss peptide in the Body Pharm range. Its triple GLP-1/GIP/glucagon agonism produced 24.2% mean weight loss at 48 weeks in the 2023 Phase 2 trial, exceeding published tirzepatide and semaglutide results [5][6].

Next Steps

Researchers ready to select a peptide should first review the Retatrutide vs Semaglutide vs Tirzepatide comparison to match receptor coverage against your protocol's mechanistic endpoints. Once you have identified the compound, consult the corresponding dosing guide, how to dose Retatrutide, how to dose Tirzepatide, how to dose Cagrisema, how to dose Semaglutide, or how to dose Tesamorelin, to map your titration schedule and vial strength selection. Then confirm current 2026 GBP pricing and batch availability on the Body Pharm UK product page before placing your order.

References

1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov/35658024
3. MHRA classification of research peptides as medicinal products by presentation and intended use (Human Medicines Regulations 2012). Regulatory position; no single specific publication cited — unlinked.
4. Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021. pubmed.ncbi.nlm.nih.gov/33894838
5. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
6. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov/33567185
7. UK marketing authorisation and NHS access for licensed weight-loss medicines (Wegovy, Mounjaro, Saxenda). MHRA/NHS regulatory status; no single specific publication cited — unlinked.
8. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. Lancet. 2021. pubmed.ncbi.nlm.nih.gov/34798060
9. Enebo LB, et al. Cagrilintide plus semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021. pubmed.ncbi.nlm.nih.gov/33894838
10. Retatrutide (LY3437943) Phase 3 obesity programme — pre-publication as of 2026; no journal paper available — unlinked.
11. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
12. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med. 2007. pubmed.ncbi.nlm.nih.gov/18057338
13. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med. 2007. pubmed.ncbi.nlm.nih.gov/18057338
14. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med. 2007. pubmed.ncbi.nlm.nih.gov/18057338